🧭 Vista guiada ¿Eres nuevo en genética? Explicamos cada término mientras navegas, en un lenguaje sencillo. Las mismas páginas, con la ayuda incorporada.
⚡ Opinión experta Ya conoces la biología. Solo el contenido — limpio y compacto, sin explicaciones adicionales. Esta es la vista predeterminada.
Idioma de la interfaz
Modo claro
Nasdaq: SGMO · Richmond, California
Sangamo Therapeutics
The company that took gene editing into humans first, years before CRISPR existed as a tool.
Phase IIIZinc finger platform
En un párrafo
Long before CRISPR, Sangamo was editing human genes with zinc finger nucleases — and running the first human gene-editing trials, starting in 2009 with an HIV programme. Today it works on zinc-finger repressors for neurological disease and on the delivery capsids that get genetic medicines into the brain.
Sangamo Therapeutics, founded in 1995, pioneered zinc finger nuclease therapeutics and conducted the first human gene-editing trials, including CCR5 disruption in HIV from 2009. Current work centres on zinc finger repressors for neurological targets such as prion disease and tauopathies, and on engineered AAV capsids for central nervous system delivery — an area of value to the whole field given that delivery, not editing, is the limiting step for brain indications.
No es asesoramiento de inversión
Este perfil es información educativa recopilada a partir de comunicaciones públicas. No es una recomendación de comprar, vender o mantener ningún valor, ni una opinión sobre las perspectivas de la empresa. La biotecnología es altamente especulativa y la mayoría de los programas clínicos fracasan.
Avisos legales completos →
Written by The CRISPR Atlas editorial teamLast updated Aug 25, 2026
Connected in the Atlas
Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.
